Everhart Financial Group Inc. Takes $295,000 Position in Agilent Technologies, Inc. (NYSE:A)

Everhart Financial Group Inc. acquired a new stake in Agilent Technologies, Inc. (NYSE:A) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,277 shares of the medical research company’s stock, valued at approximately $295,000.

Several other large investors have also recently added to or reduced their stakes in A. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies in the fourth quarter valued at approximately $26,000. VisionPoint Advisory Group LLC acquired a new stake in shares of Agilent Technologies during the 4th quarter worth $29,000. Rise Advisors LLC increased its position in shares of Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after purchasing an additional 190 shares during the period. YHB Investment Advisors Inc. acquired a new position in Agilent Technologies in the first quarter valued at about $34,000. Finally, Riverview Trust Co bought a new stake in Agilent Technologies during the first quarter worth about $41,000. Institutional investors own 87.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on A shares. Wolfe Research cut Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Barclays raised their price objective on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research note on Friday. Evercore ISI boosted their target price on Agilent Technologies from $130.00 to $135.00 and gave the stock an “in-line” rating in a research note on Thursday. Finally, Robert W. Baird dropped their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and an average target price of $140.80.

Agilent Technologies Stock Up 0.5 %

NYSE A traded up $0.65 during trading hours on Friday, hitting $140.87. The company’s stock had a trading volume of 1,735,656 shares, compared to its average volume of 1,758,116. The company has a market capitalization of $41.10 billion, a PE ratio of 33.28, a price-to-earnings-growth ratio of 4.86 and a beta of 1.05. The company’s 50-day simple moving average is $134.16 and its two-hundred day simple moving average is $138.54. Agilent Technologies, Inc. has a 52 week low of $96.80 and a 52 week high of $155.35. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the prior year, the firm posted $1.43 EPS. The firm’s quarterly revenue was down 5.6% compared to the same quarter last year. Research analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total transaction of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the sale, the chief executive officer now directly owns 25,185 shares in the company, valued at $3,274,050. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now directly owns 49,486 shares in the company, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,874 shares of company stock valued at $2,811,770. 0.33% of the stock is owned by insiders.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.